Garda Therapeutics to Acquire Assertio Holdings for $125.1 Million

Zydus Worldwide DMCC to Acquire Assertio Holdings in All-Cash $166.4 Million Tender Offer

May 13, 2026

Biotechnology

Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Limited, has entered into a definitive agreement to acquire all outstanding shares of Assertio Holdings, Inc. for $23.50 per share in cash, valuing the deal at approximately $166.4 million. The transaction is structured as a tender offer followed by a second-step merger at the same price and is expected to close in the second quarter of 2026 (2026–27 financial year in some reports), subject to customary conditions.

ClinActiv Holdings Acquires Crescita Therapeutics in All-Cash Deal

March 16, 2026

Healthcare Services

Crescita Therapeutics Inc. has entered into a definitive arrangement agreement to be acquired by ClinActiv Holdings Inc. in an all-cash transaction valued at $0.80 per share (minimum $0.75 per share), subject to working-capital adjustments. The transaction is expected to close in the second quarter of 2026 and will result in Crescita shares being delisted from the Toronto Stock Exchange, with a post-closing reorganization in which ClinActiv retains the commercial skincare and contract manufacturing business.

Esperion Therapeutics to Acquire Corstasis Therapeutics

March 5, 2026

Biotechnology

Esperion Therapeutics announced it has entered into a definitive agreement to acquire Corstasis Therapeutics for an upfront cash payment of $75 million, with potential milestone payments of up to $180 million. The deal is expected to add Enbumyst (bumetanide nasal spray) to Esperion’s cardiovascular portfolio, leveraging its commercial infrastructure to expand its cardiovascular franchise.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

Pharmacosmos Acquires G1 Therapeutics

August 7, 2024

Biotechnology

Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.

Assertio Holdings Acquires Spectrum Pharmaceuticals

April 25, 2023

Pharmaceuticals

Assertio Holdings, Inc. agreed to acquire all outstanding shares of Spectrum Pharmaceuticals, Inc. in an all-stock transaction with contingent value rights (CVRs), expected to close in Q3 2023. The deal combines Assertio's digital, non-personal commercial capabilities with Spectrum's in-person commercial team and ROLVEDON (eflapegrastim-xnst) to accelerate the product's launch and broaden the combined company's pharmaceutical portfolio.